Roche’s Lebrikizumab Brings Conflicting Results in Two Phase 3 Studies

Swiss drug giant Roche’s asthma candidate lebrikizumab yielded conflicting results in two Phase 3 studies.

In one study, the candidate met its primary endpoint of a significant reduction in the rate of asthma exacerbations in people with higher levels of serum periostin or blood eosinophils. It also showed significant improvement in lung function.

The candidate, however, failed to show statistical significance in the second trial.